Biomarkers for the diagnosis and/or prognosis of clear cell renal cell carcinoma

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9523690
APP PUB NO 20150219660A1
SERIAL NO

14427285

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides an in vitro method for the diagnosis and/or prognosis of clear cell Renal Cell Carcinoma in a subject suspected of suffering it, in which method the presence and levels of a phosphorylated form of the protein Signal transducer and activator of transcription 3 (STAT3) are determined. Said determination is performed in any isolated sample, in particular in a biopsy of a tumor. The invention relates also to the use of means for detecting said phosphorylated form to be applied in the method for the diagnosis and/or prognosis of clear cell Renal Cell Carcinoma.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA08035 BARCELONA

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Cuadros, Arasa Thais Barcelona, ES 1 1
Meseguer, Navarro Anna Barcelona, ES 1 1

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 20, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00